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esponsibility of InstAbstract Brain delivery of macromolecular therapeutics (e.g., proteins) remains an unsolved problem because
of the formidable blood–brain barrier (BBB). Although a direct pathway of nose-to-brain transfer provides an
answer to circumventing the BBB and has already been intensively investigated for brain delivery of small drugs,
new challenges arise for intranasal delivery of proteins because of their larger size and hydrophilicity. In order to
overcome the barriers and take advantage of available pathways (e.g., epithelial tight junctions, uptake by
olfactory neurons, transport into brain tissues, and intra-brain diffusion), a low molecular weight protamine
(LMWP) cell-penetrating peptide was utilized to facilitate nose-to-brain transport. Cell-penetrating peptides (CPP)
have been widely used to mediate macromolecular delivery through many kinds of biobarriers. Our results show
that conjugates of LMWP–proteins are able to effectively penetrate into the brain after intranasal administration.
The CPP-based intranasal method highlights a promising solution for protein therapy of brain diseases.
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Sciences. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1
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The blood–brain barrier (BBB) poses a formidable challenge to the
central nervous system (CNS) delivery of macromolecular ther-
apeutics. In some brain diseases pathological processes often
associate with changes in BBB permeability. As a good case in
point, leaky blood vessels are commonly found in brain cancers,
thereby contributing to the enhanced permeability and retention
(EPR) effect1. In most circumstances, however, the leakage is
generally limited to insigniﬁcant amounts of active macromole-
cules that yield little therapeutic beneﬁt. Moreover, neurodegen-
erative diseases do not induce angiogenesis and thus there is no
signiﬁcant change in BBB permeability.
Intracranial injection is the direct but difﬁcult way to deliver drugs
into the brain. Despite the high risk of surgical operations, intracranial
administration remains the primary means of direct brain drug
delivery; for instance, it is the only clinically employed method for
biomacromolecular drugs due to their inability to penetrate the BBB.
However, the BBB is not the only problem; the difﬁcult problem of
drug diffusion across CNS compartments must also be addressed.
Although intraparenchymal or CSF administration can yield a high
degree of targeting, the distribution of proteins is restricted within the
injection sites due largely to the hydrophilic nature and large size2. For
example3, diffusion coefﬁcients of proteins in the brain is estimated to
be 10–6 cm2/s. The delay or restriction of intra-tissue diffusion may
compromise the desired pharmacological efﬁcacy. Hence, the dual
barriers (i.e., BBB and intracerebral diffusion) render most efforts to
deliver protein drugs into brain a failure. Therefore, the need for new
techniques to overcome the BBB and deliver drugs into the CNS
remains exigent.
Nasal administration using the olfactory axonal pathway from
the epithelium into cerebral tissue for drug delivery has attracted
scientiﬁc attention for its circumvention of BBB and ease of
administration. The research focus of nose-to-brain delivery,
however, has been most prominently focused on small drugs,
because the tight intercellular junctions in the nasal mucous
membranes normally prevent the passage of drugs with molecular
weights greater than 1000 Da. Apart from the tight junction
barrier, migration along olfactory axons presents an additional
obstacle for the delivery of proteins because of their poor cell
penetration ability. Some viruses4 and phage-display peptide
sequences5 have been reported to reach the CNS via olfactory
axonal transport, but so far little is known about the feasibility of
the olfactory axonal delivery of macromolecular therapeutics.Figure 1 The cell-penetrating LMWP peptide-medCell-penetrating peptides (CPPs), also known as protein trans-
duction domains (PTDs), have been extensively explored for their
potential application in mediating biomacromolecular drug deliv-
ery6. The CPP-based intracellular delivery has been shown to be
cell-type independent7, and able to penetrate across various
biobarriers (e.g., retina and neurons8,9, blood brain barrier10,11,
intestine wall12–14, and skin15,16) that otherwise constitute great
impediments to conventional approaches of macromolecular drug
delivery. Therefore, CPPs are a powerful tool for mediating
protein delivery.
Low molecular weight protamine (LMWP) is a nature-sourced
CPP with the sequence of VSRRRRRRGGRRRR, ﬁrstly identiﬁed
by our laboratory from enzymatically-digested fractions of prota-
mine. In our previous studies the ability of LMWP-mediated
transcutaneous delivery has been demonstrated16,17. More inter-
estingly, LMWP was also found to be able to mediate nose-to-
brain delivery of nanoparticles18. Therefore we were motivated to
develop a nose-to-brain protein delivery system by conjugating a
CPP to a protein molecule (Fig. 1).2. Experimental
LMWP was prepared by digestion of native protamine using an
enzymatic method we reported previously19. Three model proteins,
bovine serum albumin (BSA, Sigma–Aldrich), peroxidase (HRP,
Sigma–Aldrich) and β-galactosidase (β-gal, Invitrogen) were used
in the investigations. The proteins were conjugated to LMWP via a
covalent bond. In brief, LMWP in PBS (5 mg/mL) was activated
by N-succinimidyl-S-acetylthioacetate (SATA, Pierce, Fisher) at a
reaction ratio of 1:3. After a 2-h incubation at room temperature
(RT), the excess SATA was removed using a heparin afﬁnity
column (HiTrap, GE Healthcare). Deacylation to generate a
sulfhydryl at the N-terminal of LMWP was accomplished using
dydroxylamine HCl. A maleimide-activated protein (10 mg/mL in
PBS) was produced by reaction with a 3-fold molar excess of
succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate
(SMCC, Pierce) for 30 min, and puriﬁed using a desalting column.
The thiolated LMWP and maleimide-activated protein were mixed
(5:1, mol/mol) and incubated for 2 h at r.t. to produce LMWP-
conjugated protein via a thioether bond. Further puriﬁcation of the
LMWP-conjugated proteins was conducted by dialysis and heparin
column as described in our previous report16. The elution obtained
from the heparin column with a gradient elution of 2 mol/L NaCliated protein drug from nose to brain delivery.
Figure 2 SDS-PAGE characterization of the LMWP–BSA conjugates.
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conﬁrmed by protein gel electrophoresis and Q-TOF-MS.
The tested compound (LMWP–BSA) was labeled with CY5-
NHS dye. BALB/c nude mice were anesthetized and placed on
their backs during the experiment. Nasal administration was
performed on anaesthetized mice as follows: The sample solution
was introduced into the nose cavity by using a PE-50 tubing with a
dose of 20 μL (10 μL per nostril). After dosing, animals were
subject to in vivo imaging by using an IVIS imaging system
(Caliper PerkinElmer, Hopkinton, MA, USA). After 8 h cardiac
perfusion was performed with PBS and the brain tissues were
collected for ﬂuorescent imaging. The animal procedures were
approved by University Committee on Use and Care of Animals
(UCUCA, University of Michigan, USA) and Institutional Com-
mittee on Use and Care of Animals (ICUCA, Shanghai Institute of
Materia Medica, Chinese Academy of Sciences, Shanghai, China).
For the intra-tissue penetration observation, the ﬂuorescein
isothiocyanate (FITC)-labeled LMWP–BSA was given to the
anesthetized BALB/c mice with treatment for 3 h. The olfactory
bulbs were then processed by cryosection and slices were then
examined using a ﬂuorescent microscope (Olympus BX-51).
A model protein, i.e., HRP or β-gal, with chemical linkage of
LMWP was intranasally administered to the BALB/c mice. After
3 h of exposure, mice (3 per group) were killed by cardiac
perfusion with PBS. Brain tissues were collected and homogenized
using a BioMasher homogenizer (BioMasher, USA). After cen-
trifugation the supernatants were subjected to the bioactivity assay.
HRP activity in the tissues was detected by color development of
the peroxidase substrate of tetramethylbenzidine (TMB, Kirke-
gaard & Perry Laboratories, USA), and β-gal using the colori-
metric substrate of o-nitrophenyl-b-D-galactoside (ONPG, Sigma–
Aldrich, USA) according to the manufacturers' instructions.3. Results and discussion
LMWP has been utilized previously for drug delivery, including
delivery of proteins16,18–22, genes23–25, supramolecular assem-
bles26,27, and nanoparticles28. LMWP is derived from protamine
(an FDA approved clinical drug), and the preclinical safety/
toxicology proﬁle of LMWP has been evaluated, displaying
advantages of signiﬁcantly low immunogenicity and toxic
responses29–31. Furthermore, mass production of high-purity
LMWP (499%) has been established for a scale up to tens of
grams per week using an enzymatic digestion method, thereby
being more efﬁcient and economically viable as compared to the
chemical syntheses that are currently employed for production of
all other CPPs.
The ﬁnal product of LMWP–BSA after chemical conjugation
was puriﬁed by heparin column because LMWP has high afﬁnity
for the immobile heparin, thus rendering retention of LMWP–BSA
in the column. After elution with 1 mol/L NaCl solution, the purity
of the desalted sample was veriﬁed by gel electrophoresis (Fig. 2).
Moreover, Q-TOF mass spectrometry results (Fig. 3) showed that
the major product generally possessed a (2:1–3:1) molar ratio of
LMWP:BSA.
Use of CPP–protein conjugation for nasal drug delivery
targeting to brain has rarely been reported. The feasibility of
LMWP-mediated nasal delivery was investigated by using a CY5
dye-labeled LMWP–BSA conjugate. The biodistribution in brain
was observed with an IVIS™ imaging system. The in vivo
imaging revealed that both LMWP–BSA and BSA were retainedin the nasal cavity during the experiment (Fig. 4, top panel). The
tissue imaging showed that administered BSA was negligible in
the brain. However, LMWP–BSA was delivered to the brain
tissues, and exhibited signiﬁcant brain distribution with higher
intensity of ﬂuorescence found in the olfactory bulbs, while
showing moderate cerebral distribution (Fig. 4, bottom panel). In
addition, the labeled protein was not detected in the major organs,
which indicated that the intranasal absorption into circulation
system was very minor. The results conﬁrmed our speculation that
LMWP would be able to overcome the mucosal tight junction
barrier, axon intracellular trafﬁcking, and intra-tissue diffusion.
Diffusional limitation is a formidable hurdle for conventional
protein delivery. In theory, the diffusion time is related to the
square of the distance for small molecules, and therefore doubling
distance results in an increase in diffusion time by 4-fold32.
Signiﬁcantly slower is the intra-tissue penetration of macromole-
cules; it may take 3 days for a 20-kDa protein to penetrate 1 mm in
brain tissue3. This limited drug exposure to pathological tissues
and cells usually produces insufﬁcient therapeutic levels, thus
severely hindering efﬁcacy in protein therapy. The LMWP-
mediated delivery was shown to be widespread over brain tissues.
Our results were in accordance with those of other groups on the
observation of extensive distribution inside brain tissues of CPP-
linked proteins10,33.
Further, the inward penetration was examined in the cryosection
slices of the olfactory bulbs. As displayed in Fig. 5, more than
spreading over the surface of brain, the proteins penetrated inside
the tissue within 1 h, reﬂected by deep-migrating ﬂuorescence. It
demonstrated the success of intra-tissue penetration of LMWP-
linked proteins, whereas the native proteins hardly showed any
tissue diffusion ability. Overall, the intra-tissue diffusion mediated
by LMWP was in a three-dimensional manner, thus enhancing the
drug exposure to the targeting tissues.
There is a lack of scrutiny on the mechanism of intra-brain
diffusion of CPP-linked proteins. Few investigations have been
conducted on the interaction of CPPs or CPP-linked proteins with
the extracellular matrix, probably due to the thinking that the
intercellular pathway does not play an important role in CPP-
mediated delivery. Indeed, CPP-mediated penetration was shown
to be by macropinocytosis in skin tissue34 and migrate deep by
saturating layer by layer of cells, indicating that the transcellular
Figure 3 Q-TOF mass spectrum of the LMWP–BSA conjugates.
Figure 4 In vivo imaging after intranasal administration (up panel) and the ﬂuorescence imaging of the brain tissues at experimental endpoint
(bottom panel).
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diffusion.
The above results demonstrated the successful nose-to-brain
delivery of LMWP–BSA by a ﬂuorescent imaging study, but it is
still necessary to determine whether a biologically active protein
could be intranasally delivered into CNS and retain activity. A
44-kD HRP or 540-kD β-gal was selected for this study. HRP is
relatively large molecule that has no known tissue receptor35 and
its brain uptake is therefore strictly controlled by the CPP-
mediated mechanism. The large size of β-gal also makes it
impossible to penetrate mucosal tight junctions. Thebiodistribution was parallel to the results of ﬂuorescent imaging.
The assay showed that enzyme activity in all the brain tissues
remained at a background level for non-conjugated HRP or β-gal,
whereas the high activity was detected in brain tissues for the
LMWP-linked enzymes (Fig. 6). This demonstrates that the
enzymes retain their functions after nose-to-brain delivery.
The accumulation of the active enzymes was found to be the
highest in the olfactory bulbs, and next was cerebrum and then
cerebellum, relating to the migration distance along the route from
nose to brain. Although protein drugs are particularly vulnerable to
normal protein degradation pathways in the body, our results clearly
Figure 5 LMWP–BSA conjugates were intranasally administered to mice. One hour later, the olfactory bulbs were removed and processed
cryosection. Slides were observed using ﬂuorescent microscope. (A) LMWP–BSA–FITC; (B) BSA–FITC.
Figure 6 Enzymatic activity of HPR (left panel) and β-gal (right panel). LMWP-linked proteins were represented by grey bars, and native
proteins white bars. LMWP-enzymes were signiﬁcantly higher than their non-modiﬁed counterparts (n¼3).
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remote delivery through the heterogeneous environments from nose
to brain.
Endocytosis plays an important role in CPP-mediated intracel-
lular delivery. Its mechanism involves the preferential binding
with heparin sulfate glycosaminoglycans on the cell surface, which
then initializes the endocytosis36. However, the intra-tissue pene-
tration mechanisms are largely unknown, and probably occur via
an extracellular pathway or layer-by-layer saturation and diffusion.
There is still much work to do to elucidate the details.
It should be noted that although we did not examine neuro-
toxicity in this study, there are good reasons to believe the safety
of this method, based on the following facts: ﬁrst, the safety of use
of LMWP has been conﬁrmed in dogs28; second, daily injection of
a CPP-fusion protein in mice with a dose of 1 mg/kg body weightfor 14 consecutive days produced no signs of gross neurological
problems or systemic distress10.4. Conclusions
It is a long-standing problem to deliver macromolecular therapeu-
tics into the CNS due to the BBB. The lack of effective delivery
techniques largely hinders the development of many promising
active macromolecules into clinically useful drugs. Up to now,
merely a handful of clinical trials of have been conducted in brain
protein therapy, and most employ a conventional intracranial
injection procedure. On ethical grounds, it is difﬁcult to justify
such an invasive protein therapy for patients. This fact to a great
extent restricts large-scale clinical trials and delays the
Nose-to-brain delivery of macromolecules 357development of protein drugs for brain diseases. Therefore there is
a pressing need for novel brain delivery techniques. Nasal delivery
provides a promising noninvasive solution for circumventing the
BBB by a direct transport of drugs into the brain via the olfactory
pathway. Although many investigations have been conducted in
nose-to-brain delivery, very few of them have looked at protein
drugs, of which the high hydrophilicity and large size limits their
ability to: (1) penetrate through the mucosal tight junction barrier;
(2) be taken up by and transported along olfactory neurons; and
(3) effectively diffuse into brain tissues. We conjugated LMWP to
several protein drugs and took advantage of its penetration ability
to mediate nose-to-brain delivery of proteins and circumvent the
BBB. Various proteins were successfully delivered intranasaly into
the brain by means of conjugating to LMWP. This study
demonstrates the promise of achieving a protein therapy for
CNS diseases by a noninvasive, simple yet effective drug delivery
system.Acknowledgments
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